Thyroid Eye Disease: Addressing the Need for Early Intervention and Comanagement

1.25 CME
75 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Thyroid Eye Disease: Addressing the Need for Early Intervention and Comanagement

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Horizon Therapeutics Ireland DAC.


Activity Description

Thyroid eye disease (TED) is a multifactorial, autoimmune disorder with a wide spectrum of signs and symptoms. It is frequently misdiagnosed, due to both the heterogeneous clinical presentation and a failure on the part of clinicians to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at increased risk for complications; however, a differential diagnosis can be achieved with the assistance of imaging. Early diagnosis and treatment can limit disfigurement and reduce vision loss. Endocrinologists, ophthalmologists, and other health care professionals involved in the management of patients with TED should be knowledgeable about both conventional and new therapies available for the treatment of patients with TED and how to apply this information into practice. In this case-based activity, expert faculty discuss the need for early intervention and comanagement as well as available treatment options for patients with TED.


Target Audience

The intended audience for this activity is endocrinologists, ophthalmologists, and other health care professionals involved in the management of people with thyroid eye disease (TED).


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review evidence-based recommendations regarding the differentiation and assessment of disease activity to aid in earlier diagnosis, classification, and treatment of thyroid eye disease.
  • Assess current evidence regarding the efficacy, safety, benefits, and limitations of conventional and new therapies for the treatment of thyroid eye disease.
  • Summarize best practices for treatment and referral that can improve the multidisciplinary comanagement of patients with thyroid eye disease.

Activity Chair

Terry J. Smith, MD
Frederick G.L. Huetwell Professor
Ophthalmology and Visual Sciences
Professor of Internal Medicine
University of Michigan Medical School
Ann Arbor, MI


Faculty

Raymond S. Douglas, MD, PhD
Professor of Surgery
Division of Ophthalmology
Director, Orbital and Thyroid Eye Disease Program
Cedars-Sinai Medical Center
Los Angeles, CA

George J. Kahaly, MD, PhD
Professor of Medicine and Endocrinology/Metabolism
Department of Medicine
Johannes Gutenberg University Medical Center
Mainz, Germany


Medical Writer

Valerie Zimmerman, PhD

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Douglas, Kahaly, and Smith during a live satellites symposium held on Sunday, September 11, 2022 in Brussels, Belgium. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 30, 2022, to December 29, 2023.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Raymond S. Douglas, MD, PhD
Employee: RVL Pharmaceuticals*
Consultant: Horizon, Valencia Bio Pharma, VasaraGen, Viridian

George J. Kahaly, MD, PhD
Consultant: Immunovant, VasaraGen
Independent Research Contractor (paid to institution): Horizon, Immunovant, Roche

Terry J. Smith, MD
Consultant: Escient, Horizon, Lundbeck, Retune, Viridian

Medical Writer reports the following relevant financial relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

*The contents of this activity are not related to the business lines or products of the employer.

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com